...
aneb-img

Anebulo Pharmaceuticals Inc, Common Stock

ANEB

NAQ

$2.83

-$0.18

(-5.98%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$77.16M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
5.79K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
3.69K
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.99
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.62 L
$4.05 H
$2.83

About Anebulo Pharmaceuticals Inc, Common Stock

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameANEBSectorS&P500
1-Week Return2.03%1.96%1.86%
1-Month Return15.77%1.41%1.29%
3-Month Return22.36%-0.06%4.3%
6-Month Return40%14.64%19.12%
1-Year Return30.87%9.92%28.17%
3-Year Return-57.3%21.12%30.48%
5-Year Return-57.61%76.06%96.57%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses173.35K3.61M3.61M6.83M11.78M[{"date":"2019-12-31","value":1.47,"profit":true},{"date":"2020-12-31","value":30.67,"profit":true},{"date":"2021-12-31","value":30.67,"profit":true},{"date":"2022-12-31","value":57.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(173.35K)(3.61M)(3.61M)(6.83M)(11.78M)[{"date":"2019-12-31","value":-17335000,"profit":false},{"date":"2020-12-31","value":-361375300,"profit":false},{"date":"2021-12-31","value":-361375300,"profit":false},{"date":"2022-12-31","value":-683117400,"profit":false},{"date":"2023-12-31","value":-1178359900,"profit":false}]
Total Non-Operating Income/Expense-26.63M(26.63M)97.96K106.46K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-100.01,"profit":false},{"date":"2022-12-31","value":0.37,"profit":true},{"date":"2023-12-31","value":0.4,"profit":true}]
Pre-Tax Income(174.64K)(30.25M)(30.25M)(6.83M)(11.73M)[{"date":"2019-12-31","value":-17463700,"profit":false},{"date":"2020-12-31","value":-3025255400,"profit":false},{"date":"2021-12-31","value":-3025255400,"profit":false},{"date":"2022-12-31","value":-682561900,"profit":false},{"date":"2023-12-31","value":-1173233800,"profit":false}]
Income Taxes(1.04K)-10.75K-(104.19K)[{"date":"2019-12-31","value":-9.68,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-969.49,"profit":false}]
Income After Taxes--(30.26M)-(11.63M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-3026330100,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-1162814740,"profit":false}]
Income From Continuous Operations-(30.25M)(6.83M)(11.73M)(11.60M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-3025255400,"profit":false},{"date":"2021-12-31","value":-682561900,"profit":false},{"date":"2022-12-31","value":-1173233800,"profit":false},{"date":"2023-12-31","value":-1160132600,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(174.64K)(30.25M)(30.26M)(6.83M)(11.73M)[{"date":"2019-12-31","value":-17463700,"profit":false},{"date":"2020-12-31","value":-3025255400,"profit":false},{"date":"2021-12-31","value":-3026330100,"profit":false},{"date":"2022-12-31","value":-682561900,"profit":false},{"date":"2023-12-31","value":-1173233800,"profit":false}]
EPS (Diluted)-(0.32)(2.40)(0.44)(0.42)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-32.38,"profit":false},{"date":"2021-12-31","value":-240,"profit":false},{"date":"2022-12-31","value":-44,"profit":false},{"date":"2023-12-31","value":-42,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ANEB
Cash Ratio 6.56
Current Ratio 6.73

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ANEB
ROA (LTM) -54.65%
ROE (LTM) -95.37%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ANEB
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ANEB
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 11.61
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

News

New Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What’s the Latest?

Anebulo Pharmaceuticals, Inc. (ANEB) has disclosed a new risk, in the Debt & Financing category. Anebulo Pharmaceuticals, Inc. has undertaken a sig…

15 Feb, 2024 a 6:02 am TipRanks

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three and twelve months ended June 30, 2023, and recent updates. Fourth Quarter Fiscal Year 2023 and Subsequent Highlights:

20 Sep, 2023 a 8:29 pm Wallstreet:Online

Anebulo Pharmaceuticals, Inc.: Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension

FDA provides favorable input on studies to support ANEB-001 approval Part C Extension of Phase 2 trial completed exploring THC challenge dose of up to 60 mg Anebulo Pharmaceuticals, Inc. (Nasdaq: …

21 Aug, 2023 a 12:06 pm Finanz Nachrichten

FAQs

What is Anebulo Pharmaceuticals Inc share price today?

Anebulo Pharmaceuticals Inc (ANEB) share price today is $2.83

Can Indians buy Anebulo Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Anebulo Pharmaceuticals Inc (ANEB) on Vested. To buy Anebulo Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANEB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Anebulo Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Anebulo Pharmaceuticals Inc (ANEB) via the Vested app. You can start investing in Anebulo Pharmaceuticals Inc (ANEB) with a minimum investment of $1.

How to invest in Anebulo Pharmaceuticals Inc shares from India?

You can invest in shares of Anebulo Pharmaceuticals Inc (ANEB) via Vested in three simple steps:

  • Click on Sign Up or Invest in ANEB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Anebulo Pharmaceuticals Inc shares
What is Anebulo Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Anebulo Pharmaceuticals Inc (ANEB) is $4.05. The 52-week low price of Anebulo Pharmaceuticals Inc (ANEB) is $1.62.

What is Anebulo Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Anebulo Pharmaceuticals Inc (ANEB) is

What is Anebulo Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Anebulo Pharmaceuticals Inc (ANEB) is 11.61

What is Anebulo Pharmaceuticals Inc dividend yield?

The dividend yield of Anebulo Pharmaceuticals Inc (ANEB) is 0.00%

What is the Market Cap of Anebulo Pharmaceuticals Inc?

The market capitalization of Anebulo Pharmaceuticals Inc (ANEB) is $77.16M

What is Anebulo Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Anebulo Pharmaceuticals Inc is ANEB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top